The most common adverse effects (>0.2%) in clinical studies were nausea, headache, injection site pain, injection site coldness, and burning sensation. Drugs with gadolinium-based contrasting agents can increase the risk of [[nephrogenic systemic fibrosis]] (NSF) for those with impaired elimination of the drug. Those most at risk for NSF include patients with chronic or severe kidney disease and acute kidney injury.<ref name=USlabel2013/><ref>{{cite journal|last1=Todd|first1=DJ|last2=Kay|first2=J|title=Gadolinium-Induced Fibrosis.|journal=Annual Review of Medicine|date=2016|volume=67|pages=273â€“91|pmid=26768242}}</ref>
